Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 3/2022

Open Access 01-03-2022 | Affective Disorder | Original Article

Low serum uric acid levels are associated with the nonmotor symptoms and brain gray matter volume in Parkinson’s disease

Authors: Xiaoxue Shi, Jinhua Zheng, Jianjun Ma, Zhidong Wang, Wenhua Sun, Mingjian Li, Shen Huang, Shiyu Hu

Published in: Neurological Sciences | Issue 3/2022

Login to get access

Abstract

Background

Uric acid (UA) plays a protective role in Parkinson’s disease (PD). To date, studies on the relationship between serum UA levels and nonmotor symptoms and brain gray matter volume in PD patients have been rare.

Methods

Automated enzymatic analysis was used to determine serum UA levels in 68 healthy controls and 88 PD patients, including those at the early (n = 56) and middle-late (n = 32) stages of the disease. Evaluation of motor symptoms and nonmotor symptoms in PD patients was assessed by the associated scales. Image acquisition was performed using a Siemens MAGNETOM Prisma 3 T MRI scanner.

Results

Serum UA levels in early stage PD patients were lower than those in healthy controls, and serum UA levels in the middle-late stage PD patients were lower than those in the early stage PD patients. Serum UA levels were significantly negatively correlated with the disease course, dysphagia, anxiety, depression, apathy, and cognitive dysfunction. ROC assessment confirmed that serum UA levels had good predictive accuracy for PD with dysphagia, anxiety, depression, apathy, and cognitive dysfunction. Furthermore, UA levels were significantly positively correlated with gray matter volume in whole brain.

Conclusions

This study shows that serum UA levels were correlated with the nonmotor symptoms of dysphagia, anxiety, depression, apathy, and cognitive dysfunction and the whole-brain gray matter volume. That is the first report examining the relationships between serum UA and clinical manifestations and imaging features in PD patients.
Literature
1.
Schapira AHV, Chaudhuri KR, Jenner P (2017) Non-motor features of Parkinson disease. Nat Rev Neurosci 18(7):435–450PubMedCrossRef
2.
Eusebi P, Franchini D, De Giorgi M, Abraha I, Montedori A, Casucci P, Calabresi P, Tambasco N (2019) Incidence and prevalence of Parkinson’s disease in the Italian region of Umbria: a population-based study using healthcare administrative databases. Neurol Sci 40(8):1709–1712PubMedCrossRef
3.
Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky P, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A, Seppi K, Taba P, Vidailhet M (2013) EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol 20(1):16–34PubMedCrossRef
4.
Huang X, Ng SY, Chia NS, Acharyya S, Setiawan F, Lu ZH, Ng E, Tay KY, Au WL, Tan EK, Tan LC (2018) Serum uric acid level and its association with motor subtypes and non-motor symptoms in early Parkinson’s disease: PALS study. Parkinsonism Relat Disord 55:50–54PubMedCrossRef
5.
Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36(3):348–355PubMedCrossRef
6.
Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53(Suppl 3):S26-36 (discussion S36–8)PubMedCrossRef
7.
Kaur R, Mehan S, Singh S (2019) Understanding multifactorial architecture of Parkinson’s disease: pathophysiology to management. Neurol Sci 40(1):13–23PubMedCrossRef
8.
Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA (2005) Uric acid and oxidative stress. Curr Pharm Des 11(32):4145–4151PubMedCrossRef
9.
Kutzing MK, Firestein BL (2008) Altered uric acid levels and disease states. J Pharmacol Exp Ther 324(1):1–7PubMedCrossRef
10.
Ashburner J, Friston KJ (2000) Voxel-based morphometry—the methods. Neuroimage 11(6 Pt 1):805–821PubMedCrossRef
11.
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184PubMedPubMedCentralCrossRef
12.
Ou R, Cao B, Wei Q, Hou Y, Xu Y, Song W, Zhao B, Shang H (2017) Serum uric acid levels and freezing of gait in Parkinson’s disease. Neurol Sci 38(6):955–960PubMedCrossRef
13.
Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl LD (2004) Movement Disorder Society Task Force on Rating Scales for Parkinson’s, Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19(9):1020–8PubMedCrossRef
14.
Gallagher DA, Goetz CG, Stebbins G, Lees AJ, Schrag A (2012) Validation of the MDS-UPDRS part I for nonmotor symptoms in Parkinson’s disease. Mov Disord 27(1):79–83PubMedCrossRef
15.
16.
Moccia M, Pappata S, Erro R, Picillo M, Vitale C, Amboni M, Longo K, Palladino R, Barone P, Pellecchia MT (2015) Uric acid relates to dopamine transporter availability in Parkinson’s disease. Acta Neurol Scand 131(2):127–131PubMedCrossRef
17.
Annanmaki T, Muuronen A, Murros K (2007) Low plasma uric acid level in Parkinson’s disease. Mov Disord 22(8):1133–1137PubMedCrossRef
18.
Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Flint Beal M (2008) Metabolomic profiling to develop blood biomarkers for Parkinson’s disease. Brain 131(Pt 2):389–96PubMedCrossRef
19.
Church W, Ward V (1994) Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation. Brain Res Bull 33(4):419–25PubMedCrossRef
20.
Vieru E, Koksal A, Mutluay B, Dirican AC, Altunkaynak Y, Baybas S (2016) The relation of serum uric acid levels with l-Dopa treatment and progression in patients with Parkinson’s disease. Neurol Sci 37(5):743–747PubMedCrossRef
21.
Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Parkinson PI, Study Group C Hyson E Gorbold A. Rudolph K Kieburtz, S. Fahn, L. Gauger C Goetz J Seibyl M Forrest J Ondrasik (2008) Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 65(6):716–23PubMedPubMedCentralCrossRef
22.
Delle Donne KT, Sonsalla PK (1994) Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. J Pharmacol Exp Ther 271(3):1320–6PubMed
23.
Xu K, Bastia E, Schwarzschild M (2005) Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson’s disease. Pharmacol Ther 105(3):267–310PubMedCrossRef
24.
Duncan GW, Khoo TK, Yarnall AJ, O’Brien JT, Coleman SY, Brooks DJ, Barker RA, Burn DJ (2014) Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Mov Disord 29(2):195–202PubMedCrossRef
25.
Ueno T, Kon T, Haga R, Nishijima H, Arai A, Tomiyama M (2020) Assessing the relationship between non-motor symptoms and health-related quality of life in Parkinson’s disease: a retrospective observational cohort study. Neurol Sci 41(10):2867–2873PubMedCrossRef
26.
O’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ (2008) Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov Disord 23(1):101–106PubMedCrossRef
27.
Pellecchia MT, Savastano R, Moccia M, Picillo M, Siano P, Erro R, Vallelunga A, Amboni M, Vitale C, Santangelo G, Barone P (2016) Lower serum uric acid is associated with mild cognitive impairment in early Parkinson’s disease: a 4-year follow-up study. J Neural Transm (Vienna) 123(12):1399–1402CrossRef
28.
Xiu S, Zheng Z, Guan S, Zhang J, Ma J, Chan P (2017) Serum uric acid and impaired cognitive function in community-dwelling elderly in Beijing. Neurosci Lett 637:182–187PubMedCrossRef
29.
Moccia M, Picillo M, Erro R, Vitale C, Longo K, Amboni M, Santangelo G, Spina E, De Rosa A, De Michele G, Santoro L, Barone P, Pellecchia MT (2014) Is serum uric acid related to non-motor symptoms in de-novo Parkinson’s disease patients? Parkinsonism Relat Disord 20(7):772–775PubMedCrossRef
30.
31.
McFarland NR, Burdett T, Desjardins CA, Frosch MP, Schwarzschild MA (2013) Postmortem brain levels of urate and precursors in Parkinson’s disease and related disorders. Neurodegener Dis 12(4):189–198PubMedCrossRef
32.
Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P (1986) Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid, Biochem J 235(3):747–754PubMed
33.
Mueller C, Rajkumar AP, Wan YM, Velayudhan L, Ffytche D, Chaudhuri KR, Aarsland D (2018) Assessment and management of neuropsychiatric symptoms in Parkinson’s disease. CNS Drugs 32(7):621–635PubMedCrossRef
34.
Moccia M, Picillo M, Erro R, Vitale C, Longo K, Amboni M, Santangelo G, Palladino R, Capo G, Orefice G, Barone P, Pellecchia MT (2015) Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson’s disease. Eur J Neurol 22(1):93–98PubMedCrossRef
35.
36.
Fink KB, Göthert M (2007) 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 59(4):360–417PubMedCrossRef
37.
Santangelo G, Vitale C, Picillo M, Cuoco S, Moccia M, Pezzella D, Erro R, Longo K, Vicidomini C, Pellecchia MT, Amboni M, Brunetti A, Salvatore M, Barone P, Pappata S (2015) Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson’s disease patients. Parkinsonism Relat Disord 21(5):489–493PubMedCrossRef
38.
Mu L, Sobotka S, Chen J, Su H, Sanders I, Nyirenda T, Adler CH, Shill HA, Caviness JN, Samanta JE, Sue LI, Beach TG, Arizona C (2013) Parkinson’s Disease, Parkinson disease affects peripheral sensory nerves in the pharynx. J Neuropathol Exp Neurol 72(7):614–23PubMedCrossRef
39.
Mu L, Sobotka S, Chen J, Su H, Sanders I, Adler CH, Shill HA, Caviness JN, Samanta JE, Beach TG, Arizona C (2013) Parkinson’s Disease, Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol 72(2):119–29PubMedCrossRef
40.
Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A, Parkinson PI (2011) Study Group, Serum urate and probability of dopaminergic deficit in early “Parkinson’s disease.” Mov Disord 26(10):1864–8PubMedPubMedCentralCrossRef
41.
Ibarretxe-Bilbao N, Junque C, Segura B, Baggio HC, Marti MJ, Valldeoriola F, Bargallo N, Tolosa E (2012) Progression of cortical thinning in early Parkinson’s disease. Mov Disord 27(14):1746–1753PubMedCrossRef
42.
Huang TT, Hao DL, Wu BN, Mao LL, Zhang J (2017) Uric acid demonstrates neuroprotective effect on Parkinson’s disease mice through Nrf2-ARE signaling pathway. Biochem Biophys Res Commun 493(4):1443–1449PubMedCrossRef
43.
Oh YS, Kim JS, Yoo SW, Hwang EJ, Lyoo CH, Lee KS (2020) Gender difference in the effect of uric acid on striatal dopamine in early Parkinson’s disease. Eur J Neurol 27(2):258–264PubMedCrossRef
Metadata
Title
Low serum uric acid levels are associated with the nonmotor symptoms and brain gray matter volume in Parkinson’s disease
Authors
Xiaoxue Shi
Jinhua Zheng
Jianjun Ma
Zhidong Wang
Wenhua Sun
Mingjian Li
Shen Huang
Shiyu Hu
Publication date
01-03-2022
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 3/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-021-05558-8

Other articles of this Issue 3/2022

Neurological Sciences 3/2022 Go to the issue

Original Article

Assessing mood and cognitive functioning in acute stroke: clinical usability of a Visual Analogue Mood Scale (VAMS)

Original Article

Investigation of the peripheral inflammation (neutrophil–lymphocyte ratio) in two neurodegenerative diseases of the central nervous system

COVID-19

Massive cerebral venous sinus thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 serum: case report of a successful multidisciplinary approach

Original Article

Progressive supranuclear palsy with marked ventricular dilatation mimicking normal pressure hydrocephalus

COVID-19

Management of chronic migraine with medication overuse by web-based behavioral program during the COVID-19 emergency: results at 12 months

Original Article

Correlation of serotype-specific strain in patients with dengue virus infection with neurological manifestations and its outcome